These results suggest that endogenous AMPK signaling in myeloid cells, both liver-resident and infiltrating, acts to restrict fibrogenesis during CDAHFD-induced NASH progression but is not the mechanism by which metformin improves markers of NASH. The gene discussed is PRKAA2; the disease is metabolic dysfunction-associated steatohepatitis.